AKTS Stock Summary and Trading Ideas (Aktis Oncology | NASDAQ:AKTS)

Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.

Aktis Oncology trades on the NASDAQ stock market under the symbol AKTS.

As of June 26, 2026, AKTS stock price declined to $29.44 with 1,092,580 million shares trading.

AKTS has a beta of 1.98, meaning it tends to be more sensitive to market movements. AKTS has a correlation of 0.15 to the broad based SPY ETF.

AKTS has a market cap of $1.63 billion. This is considered a Small Cap stock.

Last quarter Aktis Oncology reported $3 million in Revenue and -$.38 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.05.

The top ETF exchange traded funds that AKTS belongs to (by Net Assets): IWM, VTI, VXF, IWO, SCHA.

AKTS support price is $29.19 and resistance is $33.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKTS shares will trade within this expected range on the day.